COMy 2019 | With new treatment options in myeloma, is auto-SCT still necessary?

Inger Nijhof

Inger Nijhof, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses whether there is still a need to perform autologous stem cell transplantations (auto-SCT) for patient with multiple myeloma. Dr Nijhof argues that there is not yet enough data from the clinical studies, especially surrounding overall survival rates, so we cannot be too quick to disregard the importance of auto-SCT. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video